Latest:
FDA Approval Insights: Perioperative Durvalumab for Resectable NSCLC
Drs Patel and Stiles discuss the significance of the FDA approval of perioperative durvalumab for patients with resectable non–small cell lung cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Brian A. Moore, MD, FACS
Latest:
Remote Monitoring Enhances Care for Patients With Head and Neck Cancer
If clinicians can identify complications earlier and take appropriate prophylactic or therapeutic measures, treatment plan adherence and outcomes may be improved for patients with head and neck cancer.
Brian D. Crompton, MD
Latest:
Dr. Crompton on the Potential for Liquid Biopsies in Pediatric Sarcomas
Brian D. Crompton, MD, physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the potential of liquid biopsies in the treatment of pediatric patients with sarcoma.
Brian F. Chapin, MD
Latest:
Dr. Chapin on Impact of Active Surveillance in Field of Prostate Cancer
Brian F. Chapin, MD, assistant professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses impact of active surveillance in the field of prostate cancer.
Brian G. M. Durie, MD
Latest:
Dr. Durie on a More Sensitive Automated Flow Cytometry MRD Test
Brian G.M. Durie, MD, chairman, International Myeloma Foundation, hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses a more sensitive automated flow cytometry minimal residual disease (MRD) test.
Brian G.M. Durie, MD, Robert J. Kreitman, MD
Latest:
ASH Interview Series
The December issue of Oncology & Biotech News featured highlights from the 51st American Society of Hematology (ASH) Annual Meeting and Exposition. We wrap up our ASH coverage this month with interviews on multiple myeloma with Brian G.M. Durie, MD, medical director and co-founder of the International Myeloma Foundation; chronic lymphocytic leukemia (CLL) with Robert J. Kreitman, MD, from the National Cancer Institute; and chronic myeloid leukemia (CML) with Francis J. Giles, MD, Cancer Therapy and Research Center at The University of Texas Health Science Center in San Antonio.
Brian J. Miles, MD
Latest:
Focal Therapy Evolves Into More Precise Treatment in Prostate Cancer
Historically, the management of localized prostate cancer has centered on removal or ablation of the entire gland with either extirpative surgery or radiation. However, the subsequent unacceptable adverse events profile can be devastating and life altering for many patients.
Brian M. Shuch, MD
Latest:
Dr. Shuch on the Impact of the SURTIME Trial in Advanced RCC
Brian M. Shuch, MD, director, Kidney Cancer Program, Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research, University of California, Los Angeles Institute of Urologic Oncology, discusses the impact of the phase III SURTIME study in advanced renal cell carcinoma (RCC).
Brian M. Slomovitz, MD
Latest:
ENGOT-EN20/GOG-3083/XPORT-EC-042 – A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced, or Recurrent Endometrial Carcinoma: Rationale, Methods, and Trial Design
Brian Slomovitz, MD, MS, FACOG, presents the study design, rationale, and primary endpoints of ENGOT-EN20/GOG-3083/XPORT-EC-042, which will be evaluating the efficacy of selinexor compared with placebo as maintenance therapy in patients with advanced or recurrent TP53wt endometrial cancer.
Brian M. Wolpin, MD, MPH
Latest:
Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)
Dr. Brian Wolpin discusses updated safety and efficacy results from the Phase 1 study of RMC-6236, a RAS(ON) multi-selective inhibitor, highlighting its promising activity, manageable safety profile, and encouraging survival outcomes in patients with RAS mutant pancreatic ductal adenocarcinoma.